GLP-1 telehealth ads: separating real safety concerns from panic

What did @ribbonunfiltered actually say?

The creator watched a telehealth ad and came out swinging with a series of medical claims about GLP-1 receptor agonists. The core arguments: GLP-1s are "10 times more deadly" in smaller people, long-term use causes "permanent irreversible" muscle destruction, going off them makes regain inevitable and worse than before, and any company that prescribes them to someone a doctor has turned down is "nothing but an ED supporter." She also compared using a legitimately prescribed medication to drug abuse, and suggested celebrities are canceling tours because GLP-1s are destroying their muscles.

These aren't fringe ideas. Some of them have a kernel of real concern behind them. But several are stated with a confidence that the evidence simply does not support, and a few are outright wrong in ways that could discourage people with genuine medical need from accessing treatment.

Does the science back this up?

Partially, in places, and not at all in others. The concern about prescribing GLP-1s to people below established BMI thresholds is legitimate. The muscle loss concern is real but overstated. The "10 times more deadly at smaller sizes" claim has no clinical basis in the literature.

On muscle loss: resistance of lean mass during GLP-1 use is a documented and active research concern. Wilding et al. (2021, NEJM) found that semaglutide produced significant total weight loss, but subsequent analyses noted that a meaningful proportion of that loss was lean mass, not just fat. Dahl et al. (2023, Obesity Reviews) flagged this as a clinical gap worth addressing. However, "permanent irreversible damage" is not what the studies show. Resistance training largely mitigates this effect (Bikou et al., 2023, Nutrients). The creator is pointing at a real issue and then dramatically overshooting it.

On weight regain after stopping: she is correct that discontinuation without behavioral change leads to significant rebound. The STEP 4 trial (Rubino et al., 2021, JAMA) showed patients who stopped semaglutide regained two-thirds of their lost weight within a year. That part checks out. The framing that your body is "shocked" and regain becomes uniquely permanent does not have clinical support.

What did they get wrong (or right)?

Let's be direct. The "10 times more deadly" claim for smaller patients is not sourced anywhere in the peer-reviewed literature. It sounds authoritative, but it is not a recognized pharmacological principle. GLP-1 receptor agonists do carry risks at any body weight, including pancreatitis, gastroparesis, and thyroid concerns, but mortality risk is not linearly or exponentially tied to starting BMI in this way.

The eating disorder framing is where this gets genuinely complicated. Clinicians do flag that GLP-1 use in people without obesity-related comorbidities and below clinical thresholds raises questions. That is a fair point. But calling a platform an "ED supporter" because it uses telehealth prescribing is a serious accusation that conflates a legitimate systemic concern with a sweeping moral condemnation.

What she got right: weight regain on discontinuation is real and documented. Prescribing to patients who fall below clinical criteria is a legitimate regulatory and safety concern. The framing that these are tools, not permanent fixes, is consistent with clinical guidance from the American Diabetes Association and the Obesity Society.

What should you actually know?

GLP-1 receptor agonists are approved for specific populations. Semaglutide (Wegovy) is FDA-approved for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. Prescribing outside those parameters is not automatically dangerous, but it does move outside the evidence base that established safety and efficacy. That matters.

Muscle loss during GLP-1 treatment is real and worth managing proactively. Adequate protein intake and resistance exercise are the primary mitigations, and these are increasingly included in clinical guidance. This is not a reason to avoid treatment; it is a reason to treat comprehensively.

On rebound weight gain: the evidence is clear that GLP-1s work while you take them and that stopping without sustainable habit change leads to regain. That is not unique to GLP-1s. It applies to most pharmacological weight interventions. The creator is right to raise it. She is wrong to frame it as a permanent, irreversible bodily catastrophe for which there is no clinical evidence.

If you have been told by one provider that GLP-1s are not appropriate for you, seeking a second opinion is not the same as "abusing substances." But if multiple clinicians have declined and you are shopping for a yes, that pattern is worth examining honestly with a qualified provider, not a TikTok comment section.